Cancers (Basel) 2021 Mar 29;13(7). Epub 2021 Mar 29.
Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, FL 33612, USA.
Multi-gene assays often include and, in certain instances, may report associated toxicity risks for irinotecan, belinostat, pazopanib, and nilotinib. However, guidance for incorporating results into therapeutic decision-making is mostly lacking for these anticancer drugs. We summarized meta-analyses, genome-wide association studies, clinical trials, drug labels, and guidelines relating to the impact of polymorphisms on irinotecan, belinostat, pazopanib, or nilotinib toxicities. Read More